CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
1 - 20 . (canceled)
21 . A method of treating a middle or inner ear disease comprising intratympanically administering to a patient in need thereof a controlled release composition comprising a fluoroquinolone and a poloxamer, wherein the poloxamer has a concentration of about 20% (w/w) or lower.
22 . The method of claim 21 , wherein the fluoroquinolone is suspended in the composition.
23 . The method of claim 21 , wherein the composition is a suspension in which the fluoroquinolone is dispersed within the poloxamer.
24 . The method of claim 21 , wherein the poloxamer is poloxamer 407.
25 . The method of claim 21 , wherein the composition provides controlled release of the fluoroquinolone over an extended period of time of one or more days.
26 . The method of claim 21 , wherein the composition further comprises a phosphate which buffers the pH of the composition to about 7.4.
27 . The method of claim 21 , wherein the composition is contained in a syringe optionally connected to a needle.
28 . The method of claim 27 , wherein a single dose of the composition in the syringe is about 200 μL to about 500 μL.
29 . The method of claim 21 , wherein the composition is administered by inserting it into the middle ear.
30 . The method of claim 21 , wherein the composition is administered by infusion, injection, or by deposition by means of a surgical instrument.
31 . The method of claim 21 , wherein the middle or inner ear disease is selected from the group consisting of tinnitus, hearing loss, inner ear inflammations or infections, auto-immune disorders, vertigo, and Meniere's Disease.
32 . The method of claim 31 , wherein the tinnitus comprises cochlear tinnitus.
33 . The method of claim 21 , wherein the middle or inner ear disease is excitotoxicity-induced ear cell degeneration or age-induced ear cell degeneration.
34 . The method of claim 21 , wherein the treatment comprises reducing the perception of tinnitus or sound.
35 . The method of claim 21 , wherein the middle ear disease is a viral or a bacterial infection disease.